{"schema_version":"secwatch.filing_event.v1","accession":"0001125345-24-000161","form_type":"8-K","ticker":"MGNX","cik":"0001125345","company_name":"MACROGENICS INC","filed_at":"2024-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.728435+00:00","generated_at":"2026-05-30T05:09:35.786063+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MacroGenics Q3 net income $56.3M; cash runway into 2026; MARGENZA sale progress","bullets":["Net income $56.3M ($0.90 diluted EPS) vs $17.6M in Q3 2023; revenue $110.7M driven by $100M Incyte milestone.","Cash $200.4M at Sep 30; plus $40M MARGENZA upfront from TerSera, less $8M fee; runway into 2026.","MARGENZA sale to TerSera for $40M upfront + up to $35M milestones; closing expected Q4 2024.","IND for ADAM9-targeting ADC MGC028 submitted; TAMARACK mCRPC study continues, rPFS data early 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001125345-24-000161","json":"https://secwatch.observer/filing/0001125345-24-000161.json","markdown":"https://secwatch.observer/filing/0001125345-24-000161.md","text":"https://secwatch.observer/filing/0001125345-24-000161.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1125345/000112534524000161/0001125345-24-000161-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1125345/000112534524000161/mgnx-20241105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:09:35.786063+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}